Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV.

PubWeight™: 1.77‹?› | Rank: Top 3%

🔗 View Article (PMID 17640321)

Published in Am J Gastroenterol on July 19, 2007


Thomas D Schiano1, Donald P Kotler, Elena Ferran, M Isabel Fiel

Author Affiliations

1: The Recanati/Miller Transplantation Institute, and the Division of Liver Diseases, Department of Medicine, The Mount Sinai Medical Center, New York, New York 10029, USA.

Articles citing this

Human immunodeficiency virus infection and the liver. World J Hepatol (2012) 0.98

Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis (2012) 0.98

HIV and liver disease forum: conference proceedings. Hepatology (2007) 0.93

The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch (2010) 0.93

Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol (2010) 0.90

Role of liver transplantation in human immunodeficiency virus positive patients. World J Gastroenterol (2015) 0.85

Obliterative portal venopathy: a clinical and histopathological review. Dig Dis Sci (2013) 0.84

Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and Emerging Newer Treatment Options. J Clin Exp Hepatol (2014) 0.84

Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One (2013) 0.83

HAART and the liver: friend or foe? Eur J Med Res (2010) 0.82

Hepatoportal sclerosis in childhood: descriptive analysis of 12 patients. J Korean Med Sci (2013) 0.82

Didanosine Exposure and Noncirrhotic Portal Hypertension in a HIV Clinic in North America: a Follow-up Study. Br J Med Med Res (2011) 0.80

Human immunodeficiency virus and liver disease: An update. Hepatology (2015) 0.80

Progression of Hepatic Adenoma to Carcinoma in the Setting of Hepatoportal Sclerosis in HIV Patient: Case Report and Review of the Literature. Case Reports Hepatol (2016) 0.75

Response to Schiano et al. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol (2008) 0.75

Non-cirrhotic portal hypertension in human immunodeficiency virus-infected patients: a new challenge in antiretroviral therapy era. Open AIDS J (2011) 0.75

Elevated levels of circulating angiotensin converting enzyme in patients with hepatoportal sclerosis. Dig Dis Sci (2011) 0.75

Articles by these authors

(truncated to the top 100)

Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr (2002) 3.33

Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22

State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98

Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol (2007) 1.90

Body-size dependence of resting energy expenditure can be attributed to nonenergetic homogeneity of fat-free mass. Am J Physiol Endocrinol Metab (2002) 1.82

Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78

Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am J Clin Nutr (2007) 1.63

Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. J Clin Invest (2013) 1.57

Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. J Appl Physiol (1985) (2004) 1.57

Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52

Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48

Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44

Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. AIDS Read (2005) 1.40

Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS (2008) 1.38

Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr (2007) 1.37

Body cell mass: model development and validation at the cellular level of body composition. Am J Physiol Endocrinol Metab (2003) 1.33

Diffusion-weighted imaging of the liver with multiple b values: effect of diffusion gradient polarity and breathing acquisition on image quality and intravoxel incoherent motion parameters--a pilot study. Radiology (2012) 1.31

Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism (2006) 1.29

HIV infection and the gastrointestinal tract. AIDS (2005) 1.26

Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24

Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab (2007) 1.24

Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol (2005) 1.21

Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab (2003) 1.19

Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther (2007) 1.14

Accelerated gastric emptying but no carbohydrate malabsorption 1 year after gastric bypass surgery (GBP). Obes Surg (2012) 1.07

Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr (2002) 1.06

Multicomponent methods: evaluation of new and traditional soft tissue mineral models by in vivo neutron activation analysis. Am J Clin Nutr (2002) 1.03

The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol (2009) 1.01

Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr (2002) 1.01

Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. J Immunotoxicol (2009) 1.01

Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis (2001) 1.01

Total body protein: a new cellular level mass and distribution prediction model. Am J Clin Nutr (2003) 0.98

Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg (2002) 0.98

The virotoxin model of HIV-1 enteropathy: involvement of GPR15/Bob and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in the HT-29-D4 intestinal cell line. J Biomed Sci (2003) 0.97

Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals. J Gerontol A Biol Sci Med Sci (2011) 0.96

Lymphogranuloma venereum in human immunodeficiency virus-infected individuals in New York City. J Clin Gastroenterol (2006) 0.95

Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2004) 0.95

Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 0.94

HIV enteropathy: crypt stem and transit cell hyperproliferation induces villous atrophy in HIV/Microsporidia-infected jejunal mucosa. AIDS (2007) 0.94

Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res (2011) 0.94

The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch (2010) 0.93

Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl (2009) 0.90

Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl (2006) 0.90

Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr (2006) 0.89

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. PLoS One (2013) 0.88

DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. J Magn Reson Imaging (2013) 0.88

Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis (2012) 0.88

Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature. Am J Surg Pathol (2011) 0.87

Hepatocellular carcinoma associated with an atypical presentation of Wilson's disease. Semin Liver Dis (2007) 0.87

Impact of intrahepatic hepatitis B DNA and covalently closed circular DNA on survival after hepatectomy in HBV-associated hepatocellular carcinoma patients. Ann Surg Oncol (2013) 0.87

Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis (2009) 0.86

Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum. J Acquir Immune Defic Syndr (2006) 0.86

Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. J Acquir Immune Defic Syndr (2008) 0.85

The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab (2011) 0.85

Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis (2013) 0.85

Invasive colloid carcinoma arising from intraductal papillary neoplasm in a 50-year-old woman with primary sclerosing cholangitis. Semin Liver Dis (2004) 0.84

Recurrent hepatic sarcoidosis post-liver transplantation manifesting with severe hypercalcemia: a case report and review of the literature. Liver Transpl (2005) 0.84

Obliterative portal venopathy: a clinical and histopathological review. Dig Dis Sci (2013) 0.84

Liver failure in an antimitochondrial antibody-positive patient with sarcoidosis: primary biliary cirrhosis or hepatic sarcoidosis? Semin Liver Dis (2005) 0.84

Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. Liver Int (2014) 0.83

Effect of HIV infection on body composition and fat distribution in Rwandan women. J Int Assoc Physicians AIDS Care (Chic) (2010) 0.82

Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl (2005) 0.82

Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol (2014) 0.82

HIV enteropathy and aging: gastrointestinal immunity, mucosal epithelial barrier, and microbial translocation. Curr Opin HIV AIDS (2014) 0.82

Lipodystrophy in HIV patients: its challenges and management approaches. HIV AIDS (Auckl) (2011) 0.81

A Case of Staphylococcus aureus Enterocolitis: A Rare Entity. Gastroenterol Hepatol (N Y) (2010) 0.81

Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl (2008) 0.81

Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics. Arch Pathol Lab Med (2014) 0.81

Hepatoportal sclerosis: CT and MRI appearance with histopathologic correlation. AJR Am J Roentgenol (2012) 0.81

Diagnosis of 6 mercaptopurine hepatotoxicity post liver transplantation utilizing metabolite assays. Am J Transplant (2004) 0.81

Gastric carcinoids in a patient with pernicious anemia and familial adenomatous polyposis. J Clin Gastroenterol (2002) 0.80

Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men. Antivir Ther (2008) 0.80

Gastric toxoplasmosis as the presentation of acquired immunodeficiency syndrome. Arch Pathol Lab Med (2005) 0.79

Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation (2007) 0.79

Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J Appl Physiol (1985) (2003) 0.79

Liver pathology in obesity. Semin Liver Dis (2004) 0.78

Staphylococcal enterocolitis: forgotten but not gone? Dig Dis Sci (2009) 0.78

Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care. IAPAC Mon (2005) 0.78

Intermuscular adipose tissue and metabolic associations in HIV infection. Obesity (Silver Spring) (2010) 0.78

Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size. J Immunother (2016) 0.78

Advancing the diagnosis and treatment of hepatocellular carcinoma. Liver Transpl (2005) 0.77

Maternal allergy acts synergistically with cigarette smoke exposure during pregnancy to induce hepatic fibrosis in adult male offspring. J Immunotoxicol (2011) 0.77

Acute cellular rejection resulting in sinusoidal obstruction syndrome and ascites postliver transplantation. Transplantation (2011) 0.77

Effect of HIV infection on the prevalence of colorectal adenomas during screening colonoscopy. J Clin Gastroenterol (2010) 0.77

Use of a Durnin-Womersley formula to estimate change in subcutaneous fat content in HIV-infected subjects. Am J Clin Nutr (2002) 0.77

Teaching the competencies: using observed structured clinical examinations for faculty development. Am J Gastroenterol (2010) 0.77

Multiple inflammatory and serum amyloid A positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis (2008) 0.77

A comparison of abdominal subcutaneous adipose tissue pattern in obese and lean HIV-infected women. J Nutr (2005) 0.76

Health and human rights: an area of neglect in the core curriculum? J Med Ethics (2011) 0.76

HIV enteropathy: HAART reduces HIV-induced stem cell hyperproliferation and crypt hypertrophy to normal in jejunal mucosa. J Clin Pathol (2013) 0.76

Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation. Liver Transpl (2007) 0.75

Editorial comment: tackling the causes of lipoatrophy--not for the fainthearted. AIDS Read (2003) 0.75

To B(iopsy) or not to B(iopsy) …. Clin Gastroenterol Hepatol (2010) 0.75

Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts. Hepatol Res (2013) 0.75